Global Primidone Market

Primidone Comprehensive Study by Application (Epilepsy, Essential Tremor, Psychiatric Disorders), Patient Type (Adult, Pediatric), Distribution Channel (Hospitals & Clinics, Retail Pharmacies, Online Pharmacies), Dosage (50mg, 100mg, 150mg, 200mg, 250mg, Others) Players and Region - Global Market Outlook to 2026

Primidone Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Primidone Market Scope
Primidone is an aromatic anticonvulsant used to treat complex, partial, and generalized seizures. It belongs to a class of drugs known as barbiturate anticonvulsants. It works by controlling the abnormal electrical activity in the brain that occurs during a seizure. Increasing case of seizures disease among the people has led to significant growth of the global primidone market in the forecast period.

The Primidone market study is segmented, by Application (Epilepsy, Essential Tremor and Psychiatric Disorders) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Primidone market throughout the predicted period.

Bausch Health Companies Inc. (Canada), Amneal Pharmaceuticals (United States), Anda Repository, Lannett Co Inc (United States), Oxford Pharms (United States), Hikma Pharmaceuticals PLC (United Kingdom), Watson Labs (United States), Xcel Pharmaceuticals (United States), Dr. Reddys Laboratories (India) and Impax Laboratories (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Mutual Pharmaceutical Co Inc (United States) and Vintage Pharmaceuticals (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Primidone market by Type, Application and Region.

On the basis of geography, the market of Primidone has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Increasing Prevalence of Epilepsy Disease of the Brain

Market Drivers
  • Rising Prevalence of Chronic Diseases in Pediatrics and Adults
  • Increasing Demand for Primidone from the Developing Economies

Opportunities
  • Increasing Research and Development in Drug Discovery for Primidone

Restraints
  • Various Side Effects like Drowsiness, Excitation, Tiredness, Headache, and Many Others

Challenges
  • Strict Norms and Regulations


Key Target Audience
Primidone Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Report Objectives / Segmentation Covered

By Application
  • Epilepsy
  • Essential Tremor
  • Psychiatric Disorders
By Patient Type
  • Adult
  • Pediatric

By Distribution Channel
  • Hospitals & Clinics
  • Retail Pharmacies
  • Online Pharmacies

By Dosage
  • 50mg
  • 100mg
  • 150mg
  • 200mg
  • 250mg
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Chronic Diseases in Pediatrics and Adults
      • 3.2.2. Increasing Demand for Primidone from the Developing Economies
    • 3.3. Market Challenges
      • 3.3.1. Strict Norms and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increasing Prevalence of Epilepsy Disease of the Brain
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Primidone, by Application, Patient Type, Distribution Channel, Dosage and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Primidone (Value)
      • 5.2.1. Global Primidone by: Application (Value)
        • 5.2.1.1. Epilepsy
        • 5.2.1.2. Essential Tremor
        • 5.2.1.3. Psychiatric Disorders
      • 5.2.2. Global Primidone by: Patient Type (Value)
        • 5.2.2.1. Adult
        • 5.2.2.2. Pediatric
      • 5.2.3. Global Primidone by: Distribution Channel (Value)
        • 5.2.3.1. Hospitals & Clinics
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Primidone by: Dosage (Value)
        • 5.2.4.1. 50mg
        • 5.2.4.2. 100mg
        • 5.2.4.3. 150mg
        • 5.2.4.4. 200mg
        • 5.2.4.5. 250mg
        • 5.2.4.6. Others
      • 5.2.5. Global Primidone Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Primidone (Volume)
      • 5.3.1. Global Primidone by: Application (Volume)
        • 5.3.1.1. Epilepsy
        • 5.3.1.2. Essential Tremor
        • 5.3.1.3. Psychiatric Disorders
      • 5.3.2. Global Primidone by: Patient Type (Volume)
        • 5.3.2.1. Adult
        • 5.3.2.2. Pediatric
      • 5.3.3. Global Primidone by: Distribution Channel (Volume)
        • 5.3.3.1. Hospitals & Clinics
        • 5.3.3.2. Retail Pharmacies
        • 5.3.3.3. Online Pharmacies
      • 5.3.4. Global Primidone by: Dosage (Volume)
        • 5.3.4.1. 50mg
        • 5.3.4.2. 100mg
        • 5.3.4.3. 150mg
        • 5.3.4.4. 200mg
        • 5.3.4.5. 250mg
        • 5.3.4.6. Others
      • 5.3.5. Global Primidone Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Primidone (Price)
  • 6. Primidone: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bausch Health Companies Inc. (Canada)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amneal Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Anda Repository
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Lannett Co Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Oxford Pharms (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hikma Pharmaceuticals PLC (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Watson Labs (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Xcel Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Dr. Reddys Laboratories (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Impax Laboratories (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Primidone Sale, by Application, Patient Type, Distribution Channel, Dosage and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Primidone (Value)
      • 7.2.1. Global Primidone by: Application (Value)
        • 7.2.1.1. Epilepsy
        • 7.2.1.2. Essential Tremor
        • 7.2.1.3. Psychiatric Disorders
      • 7.2.2. Global Primidone by: Patient Type (Value)
        • 7.2.2.1. Adult
        • 7.2.2.2. Pediatric
      • 7.2.3. Global Primidone by: Distribution Channel (Value)
        • 7.2.3.1. Hospitals & Clinics
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Primidone by: Dosage (Value)
        • 7.2.4.1. 50mg
        • 7.2.4.2. 100mg
        • 7.2.4.3. 150mg
        • 7.2.4.4. 200mg
        • 7.2.4.5. 250mg
        • 7.2.4.6. Others
      • 7.2.5. Global Primidone Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Primidone (Volume)
      • 7.3.1. Global Primidone by: Application (Volume)
        • 7.3.1.1. Epilepsy
        • 7.3.1.2. Essential Tremor
        • 7.3.1.3. Psychiatric Disorders
      • 7.3.2. Global Primidone by: Patient Type (Volume)
        • 7.3.2.1. Adult
        • 7.3.2.2. Pediatric
      • 7.3.3. Global Primidone by: Distribution Channel (Volume)
        • 7.3.3.1. Hospitals & Clinics
        • 7.3.3.2. Retail Pharmacies
        • 7.3.3.3. Online Pharmacies
      • 7.3.4. Global Primidone by: Dosage (Volume)
        • 7.3.4.1. 50mg
        • 7.3.4.2. 100mg
        • 7.3.4.3. 150mg
        • 7.3.4.4. 200mg
        • 7.3.4.5. 250mg
        • 7.3.4.6. Others
      • 7.3.5. Global Primidone Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Primidone (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Primidone: by Application(USD Million)
  • Table 2. Primidone Epilepsy , by Region USD Million (2015-2020)
  • Table 3. Primidone Essential Tremor , by Region USD Million (2015-2020)
  • Table 4. Primidone Psychiatric Disorders , by Region USD Million (2015-2020)
  • Table 5. Primidone: by Patient Type(USD Million)
  • Table 6. Primidone Adult , by Region USD Million (2015-2020)
  • Table 7. Primidone Pediatric , by Region USD Million (2015-2020)
  • Table 8. Primidone: by Distribution Channel(USD Million)
  • Table 9. Primidone Hospitals & Clinics , by Region USD Million (2015-2020)
  • Table 10. Primidone Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 11. Primidone Online Pharmacies , by Region USD Million (2015-2020)
  • Table 12. Primidone: by Dosage(USD Million)
  • Table 13. Primidone 50mg , by Region USD Million (2015-2020)
  • Table 14. Primidone 100mg , by Region USD Million (2015-2020)
  • Table 15. Primidone 150mg , by Region USD Million (2015-2020)
  • Table 16. Primidone 200mg , by Region USD Million (2015-2020)
  • Table 17. Primidone 250mg , by Region USD Million (2015-2020)
  • Table 18. Primidone Others , by Region USD Million (2015-2020)
  • Table 19. South America Primidone, by Country USD Million (2015-2020)
  • Table 20. South America Primidone, by Application USD Million (2015-2020)
  • Table 21. South America Primidone, by Patient Type USD Million (2015-2020)
  • Table 22. South America Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 23. South America Primidone, by Dosage USD Million (2015-2020)
  • Table 24. Brazil Primidone, by Application USD Million (2015-2020)
  • Table 25. Brazil Primidone, by Patient Type USD Million (2015-2020)
  • Table 26. Brazil Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 27. Brazil Primidone, by Dosage USD Million (2015-2020)
  • Table 28. Argentina Primidone, by Application USD Million (2015-2020)
  • Table 29. Argentina Primidone, by Patient Type USD Million (2015-2020)
  • Table 30. Argentina Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 31. Argentina Primidone, by Dosage USD Million (2015-2020)
  • Table 32. Rest of South America Primidone, by Application USD Million (2015-2020)
  • Table 33. Rest of South America Primidone, by Patient Type USD Million (2015-2020)
  • Table 34. Rest of South America Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 35. Rest of South America Primidone, by Dosage USD Million (2015-2020)
  • Table 36. Asia Pacific Primidone, by Country USD Million (2015-2020)
  • Table 37. Asia Pacific Primidone, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Primidone, by Patient Type USD Million (2015-2020)
  • Table 39. Asia Pacific Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 40. Asia Pacific Primidone, by Dosage USD Million (2015-2020)
  • Table 41. China Primidone, by Application USD Million (2015-2020)
  • Table 42. China Primidone, by Patient Type USD Million (2015-2020)
  • Table 43. China Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 44. China Primidone, by Dosage USD Million (2015-2020)
  • Table 45. Japan Primidone, by Application USD Million (2015-2020)
  • Table 46. Japan Primidone, by Patient Type USD Million (2015-2020)
  • Table 47. Japan Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 48. Japan Primidone, by Dosage USD Million (2015-2020)
  • Table 49. India Primidone, by Application USD Million (2015-2020)
  • Table 50. India Primidone, by Patient Type USD Million (2015-2020)
  • Table 51. India Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 52. India Primidone, by Dosage USD Million (2015-2020)
  • Table 53. South Korea Primidone, by Application USD Million (2015-2020)
  • Table 54. South Korea Primidone, by Patient Type USD Million (2015-2020)
  • Table 55. South Korea Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 56. South Korea Primidone, by Dosage USD Million (2015-2020)
  • Table 57. Taiwan Primidone, by Application USD Million (2015-2020)
  • Table 58. Taiwan Primidone, by Patient Type USD Million (2015-2020)
  • Table 59. Taiwan Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 60. Taiwan Primidone, by Dosage USD Million (2015-2020)
  • Table 61. Australia Primidone, by Application USD Million (2015-2020)
  • Table 62. Australia Primidone, by Patient Type USD Million (2015-2020)
  • Table 63. Australia Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 64. Australia Primidone, by Dosage USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Primidone, by Application USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Primidone, by Patient Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Primidone, by Dosage USD Million (2015-2020)
  • Table 69. Europe Primidone, by Country USD Million (2015-2020)
  • Table 70. Europe Primidone, by Application USD Million (2015-2020)
  • Table 71. Europe Primidone, by Patient Type USD Million (2015-2020)
  • Table 72. Europe Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 73. Europe Primidone, by Dosage USD Million (2015-2020)
  • Table 74. Germany Primidone, by Application USD Million (2015-2020)
  • Table 75. Germany Primidone, by Patient Type USD Million (2015-2020)
  • Table 76. Germany Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 77. Germany Primidone, by Dosage USD Million (2015-2020)
  • Table 78. France Primidone, by Application USD Million (2015-2020)
  • Table 79. France Primidone, by Patient Type USD Million (2015-2020)
  • Table 80. France Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 81. France Primidone, by Dosage USD Million (2015-2020)
  • Table 82. Italy Primidone, by Application USD Million (2015-2020)
  • Table 83. Italy Primidone, by Patient Type USD Million (2015-2020)
  • Table 84. Italy Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 85. Italy Primidone, by Dosage USD Million (2015-2020)
  • Table 86. United Kingdom Primidone, by Application USD Million (2015-2020)
  • Table 87. United Kingdom Primidone, by Patient Type USD Million (2015-2020)
  • Table 88. United Kingdom Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 89. United Kingdom Primidone, by Dosage USD Million (2015-2020)
  • Table 90. Netherlands Primidone, by Application USD Million (2015-2020)
  • Table 91. Netherlands Primidone, by Patient Type USD Million (2015-2020)
  • Table 92. Netherlands Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 93. Netherlands Primidone, by Dosage USD Million (2015-2020)
  • Table 94. Rest of Europe Primidone, by Application USD Million (2015-2020)
  • Table 95. Rest of Europe Primidone, by Patient Type USD Million (2015-2020)
  • Table 96. Rest of Europe Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 97. Rest of Europe Primidone, by Dosage USD Million (2015-2020)
  • Table 98. MEA Primidone, by Country USD Million (2015-2020)
  • Table 99. MEA Primidone, by Application USD Million (2015-2020)
  • Table 100. MEA Primidone, by Patient Type USD Million (2015-2020)
  • Table 101. MEA Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 102. MEA Primidone, by Dosage USD Million (2015-2020)
  • Table 103. Middle East Primidone, by Application USD Million (2015-2020)
  • Table 104. Middle East Primidone, by Patient Type USD Million (2015-2020)
  • Table 105. Middle East Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 106. Middle East Primidone, by Dosage USD Million (2015-2020)
  • Table 107. Africa Primidone, by Application USD Million (2015-2020)
  • Table 108. Africa Primidone, by Patient Type USD Million (2015-2020)
  • Table 109. Africa Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 110. Africa Primidone, by Dosage USD Million (2015-2020)
  • Table 111. North America Primidone, by Country USD Million (2015-2020)
  • Table 112. North America Primidone, by Application USD Million (2015-2020)
  • Table 113. North America Primidone, by Patient Type USD Million (2015-2020)
  • Table 114. North America Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 115. North America Primidone, by Dosage USD Million (2015-2020)
  • Table 116. United States Primidone, by Application USD Million (2015-2020)
  • Table 117. United States Primidone, by Patient Type USD Million (2015-2020)
  • Table 118. United States Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 119. United States Primidone, by Dosage USD Million (2015-2020)
  • Table 120. Canada Primidone, by Application USD Million (2015-2020)
  • Table 121. Canada Primidone, by Patient Type USD Million (2015-2020)
  • Table 122. Canada Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 123. Canada Primidone, by Dosage USD Million (2015-2020)
  • Table 124. Mexico Primidone, by Application USD Million (2015-2020)
  • Table 125. Mexico Primidone, by Patient Type USD Million (2015-2020)
  • Table 126. Mexico Primidone, by Distribution Channel USD Million (2015-2020)
  • Table 127. Mexico Primidone, by Dosage USD Million (2015-2020)
  • Table 128. Primidone Sales: by Application(Tonne)
  • Table 129. Primidone Sales Epilepsy , by Region Tonne (2015-2020)
  • Table 130. Primidone Sales Essential Tremor , by Region Tonne (2015-2020)
  • Table 131. Primidone Sales Psychiatric Disorders , by Region Tonne (2015-2020)
  • Table 132. Primidone Sales: by Patient Type(Tonne)
  • Table 133. Primidone Sales Adult , by Region Tonne (2015-2020)
  • Table 134. Primidone Sales Pediatric , by Region Tonne (2015-2020)
  • Table 135. Primidone Sales: by Distribution Channel(Tonne)
  • Table 136. Primidone Sales Hospitals & Clinics , by Region Tonne (2015-2020)
  • Table 137. Primidone Sales Retail Pharmacies , by Region Tonne (2015-2020)
  • Table 138. Primidone Sales Online Pharmacies , by Region Tonne (2015-2020)
  • Table 139. Primidone Sales: by Dosage(Tonne)
  • Table 140. Primidone Sales 50mg , by Region Tonne (2015-2020)
  • Table 141. Primidone Sales 100mg , by Region Tonne (2015-2020)
  • Table 142. Primidone Sales 150mg , by Region Tonne (2015-2020)
  • Table 143. Primidone Sales 200mg , by Region Tonne (2015-2020)
  • Table 144. Primidone Sales 250mg , by Region Tonne (2015-2020)
  • Table 145. Primidone Sales Others , by Region Tonne (2015-2020)
  • Table 146. South America Primidone Sales, by Country Tonne (2015-2020)
  • Table 147. South America Primidone Sales, by Application Tonne (2015-2020)
  • Table 148. South America Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 149. South America Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 150. South America Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 151. Brazil Primidone Sales, by Application Tonne (2015-2020)
  • Table 152. Brazil Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 153. Brazil Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 154. Brazil Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 155. Argentina Primidone Sales, by Application Tonne (2015-2020)
  • Table 156. Argentina Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 157. Argentina Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 158. Argentina Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 159. Rest of South America Primidone Sales, by Application Tonne (2015-2020)
  • Table 160. Rest of South America Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 161. Rest of South America Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 162. Rest of South America Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 163. Asia Pacific Primidone Sales, by Country Tonne (2015-2020)
  • Table 164. Asia Pacific Primidone Sales, by Application Tonne (2015-2020)
  • Table 165. Asia Pacific Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 166. Asia Pacific Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 167. Asia Pacific Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 168. China Primidone Sales, by Application Tonne (2015-2020)
  • Table 169. China Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 170. China Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 171. China Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 172. Japan Primidone Sales, by Application Tonne (2015-2020)
  • Table 173. Japan Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 174. Japan Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 175. Japan Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 176. India Primidone Sales, by Application Tonne (2015-2020)
  • Table 177. India Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 178. India Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 179. India Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 180. South Korea Primidone Sales, by Application Tonne (2015-2020)
  • Table 181. South Korea Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 182. South Korea Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 183. South Korea Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 184. Taiwan Primidone Sales, by Application Tonne (2015-2020)
  • Table 185. Taiwan Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 186. Taiwan Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 187. Taiwan Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 188. Australia Primidone Sales, by Application Tonne (2015-2020)
  • Table 189. Australia Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 190. Australia Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 191. Australia Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 192. Rest of Asia-Pacific Primidone Sales, by Application Tonne (2015-2020)
  • Table 193. Rest of Asia-Pacific Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 194. Rest of Asia-Pacific Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 195. Rest of Asia-Pacific Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 196. Europe Primidone Sales, by Country Tonne (2015-2020)
  • Table 197. Europe Primidone Sales, by Application Tonne (2015-2020)
  • Table 198. Europe Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 199. Europe Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 200. Europe Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 201. Germany Primidone Sales, by Application Tonne (2015-2020)
  • Table 202. Germany Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 203. Germany Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 204. Germany Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 205. France Primidone Sales, by Application Tonne (2015-2020)
  • Table 206. France Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 207. France Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 208. France Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 209. Italy Primidone Sales, by Application Tonne (2015-2020)
  • Table 210. Italy Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 211. Italy Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 212. Italy Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 213. United Kingdom Primidone Sales, by Application Tonne (2015-2020)
  • Table 214. United Kingdom Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 215. United Kingdom Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 216. United Kingdom Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 217. Netherlands Primidone Sales, by Application Tonne (2015-2020)
  • Table 218. Netherlands Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 219. Netherlands Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 220. Netherlands Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 221. Rest of Europe Primidone Sales, by Application Tonne (2015-2020)
  • Table 222. Rest of Europe Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 223. Rest of Europe Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 224. Rest of Europe Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 225. MEA Primidone Sales, by Country Tonne (2015-2020)
  • Table 226. MEA Primidone Sales, by Application Tonne (2015-2020)
  • Table 227. MEA Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 228. MEA Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 229. MEA Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 230. Middle East Primidone Sales, by Application Tonne (2015-2020)
  • Table 231. Middle East Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 232. Middle East Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 233. Middle East Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 234. Africa Primidone Sales, by Application Tonne (2015-2020)
  • Table 235. Africa Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 236. Africa Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 237. Africa Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 238. North America Primidone Sales, by Country Tonne (2015-2020)
  • Table 239. North America Primidone Sales, by Application Tonne (2015-2020)
  • Table 240. North America Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 241. North America Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 242. North America Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 243. United States Primidone Sales, by Application Tonne (2015-2020)
  • Table 244. United States Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 245. United States Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 246. United States Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 247. Canada Primidone Sales, by Application Tonne (2015-2020)
  • Table 248. Canada Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 249. Canada Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 250. Canada Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 251. Mexico Primidone Sales, by Application Tonne (2015-2020)
  • Table 252. Mexico Primidone Sales, by Patient Type Tonne (2015-2020)
  • Table 253. Mexico Primidone Sales, by Distribution Channel Tonne (2015-2020)
  • Table 254. Mexico Primidone Sales, by Dosage Tonne (2015-2020)
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Primidone: by Application(USD Million)
  • Table 266. Primidone Epilepsy , by Region USD Million (2021-2026)
  • Table 267. Primidone Essential Tremor , by Region USD Million (2021-2026)
  • Table 268. Primidone Psychiatric Disorders , by Region USD Million (2021-2026)
  • Table 269. Primidone: by Patient Type(USD Million)
  • Table 270. Primidone Adult , by Region USD Million (2021-2026)
  • Table 271. Primidone Pediatric , by Region USD Million (2021-2026)
  • Table 272. Primidone: by Distribution Channel(USD Million)
  • Table 273. Primidone Hospitals & Clinics , by Region USD Million (2021-2026)
  • Table 274. Primidone Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 275. Primidone Online Pharmacies , by Region USD Million (2021-2026)
  • Table 276. Primidone: by Dosage(USD Million)
  • Table 277. Primidone 50mg , by Region USD Million (2021-2026)
  • Table 278. Primidone 100mg , by Region USD Million (2021-2026)
  • Table 279. Primidone 150mg , by Region USD Million (2021-2026)
  • Table 280. Primidone 200mg , by Region USD Million (2021-2026)
  • Table 281. Primidone 250mg , by Region USD Million (2021-2026)
  • Table 282. Primidone Others , by Region USD Million (2021-2026)
  • Table 283. South America Primidone, by Country USD Million (2021-2026)
  • Table 284. South America Primidone, by Application USD Million (2021-2026)
  • Table 285. South America Primidone, by Patient Type USD Million (2021-2026)
  • Table 286. South America Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 287. South America Primidone, by Dosage USD Million (2021-2026)
  • Table 288. Brazil Primidone, by Application USD Million (2021-2026)
  • Table 289. Brazil Primidone, by Patient Type USD Million (2021-2026)
  • Table 290. Brazil Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 291. Brazil Primidone, by Dosage USD Million (2021-2026)
  • Table 292. Argentina Primidone, by Application USD Million (2021-2026)
  • Table 293. Argentina Primidone, by Patient Type USD Million (2021-2026)
  • Table 294. Argentina Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 295. Argentina Primidone, by Dosage USD Million (2021-2026)
  • Table 296. Rest of South America Primidone, by Application USD Million (2021-2026)
  • Table 297. Rest of South America Primidone, by Patient Type USD Million (2021-2026)
  • Table 298. Rest of South America Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 299. Rest of South America Primidone, by Dosage USD Million (2021-2026)
  • Table 300. Asia Pacific Primidone, by Country USD Million (2021-2026)
  • Table 301. Asia Pacific Primidone, by Application USD Million (2021-2026)
  • Table 302. Asia Pacific Primidone, by Patient Type USD Million (2021-2026)
  • Table 303. Asia Pacific Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 304. Asia Pacific Primidone, by Dosage USD Million (2021-2026)
  • Table 305. China Primidone, by Application USD Million (2021-2026)
  • Table 306. China Primidone, by Patient Type USD Million (2021-2026)
  • Table 307. China Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 308. China Primidone, by Dosage USD Million (2021-2026)
  • Table 309. Japan Primidone, by Application USD Million (2021-2026)
  • Table 310. Japan Primidone, by Patient Type USD Million (2021-2026)
  • Table 311. Japan Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 312. Japan Primidone, by Dosage USD Million (2021-2026)
  • Table 313. India Primidone, by Application USD Million (2021-2026)
  • Table 314. India Primidone, by Patient Type USD Million (2021-2026)
  • Table 315. India Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 316. India Primidone, by Dosage USD Million (2021-2026)
  • Table 317. South Korea Primidone, by Application USD Million (2021-2026)
  • Table 318. South Korea Primidone, by Patient Type USD Million (2021-2026)
  • Table 319. South Korea Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 320. South Korea Primidone, by Dosage USD Million (2021-2026)
  • Table 321. Taiwan Primidone, by Application USD Million (2021-2026)
  • Table 322. Taiwan Primidone, by Patient Type USD Million (2021-2026)
  • Table 323. Taiwan Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 324. Taiwan Primidone, by Dosage USD Million (2021-2026)
  • Table 325. Australia Primidone, by Application USD Million (2021-2026)
  • Table 326. Australia Primidone, by Patient Type USD Million (2021-2026)
  • Table 327. Australia Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 328. Australia Primidone, by Dosage USD Million (2021-2026)
  • Table 329. Rest of Asia-Pacific Primidone, by Application USD Million (2021-2026)
  • Table 330. Rest of Asia-Pacific Primidone, by Patient Type USD Million (2021-2026)
  • Table 331. Rest of Asia-Pacific Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 332. Rest of Asia-Pacific Primidone, by Dosage USD Million (2021-2026)
  • Table 333. Europe Primidone, by Country USD Million (2021-2026)
  • Table 334. Europe Primidone, by Application USD Million (2021-2026)
  • Table 335. Europe Primidone, by Patient Type USD Million (2021-2026)
  • Table 336. Europe Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 337. Europe Primidone, by Dosage USD Million (2021-2026)
  • Table 338. Germany Primidone, by Application USD Million (2021-2026)
  • Table 339. Germany Primidone, by Patient Type USD Million (2021-2026)
  • Table 340. Germany Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 341. Germany Primidone, by Dosage USD Million (2021-2026)
  • Table 342. France Primidone, by Application USD Million (2021-2026)
  • Table 343. France Primidone, by Patient Type USD Million (2021-2026)
  • Table 344. France Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 345. France Primidone, by Dosage USD Million (2021-2026)
  • Table 346. Italy Primidone, by Application USD Million (2021-2026)
  • Table 347. Italy Primidone, by Patient Type USD Million (2021-2026)
  • Table 348. Italy Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 349. Italy Primidone, by Dosage USD Million (2021-2026)
  • Table 350. United Kingdom Primidone, by Application USD Million (2021-2026)
  • Table 351. United Kingdom Primidone, by Patient Type USD Million (2021-2026)
  • Table 352. United Kingdom Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 353. United Kingdom Primidone, by Dosage USD Million (2021-2026)
  • Table 354. Netherlands Primidone, by Application USD Million (2021-2026)
  • Table 355. Netherlands Primidone, by Patient Type USD Million (2021-2026)
  • Table 356. Netherlands Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 357. Netherlands Primidone, by Dosage USD Million (2021-2026)
  • Table 358. Rest of Europe Primidone, by Application USD Million (2021-2026)
  • Table 359. Rest of Europe Primidone, by Patient Type USD Million (2021-2026)
  • Table 360. Rest of Europe Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 361. Rest of Europe Primidone, by Dosage USD Million (2021-2026)
  • Table 362. MEA Primidone, by Country USD Million (2021-2026)
  • Table 363. MEA Primidone, by Application USD Million (2021-2026)
  • Table 364. MEA Primidone, by Patient Type USD Million (2021-2026)
  • Table 365. MEA Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 366. MEA Primidone, by Dosage USD Million (2021-2026)
  • Table 367. Middle East Primidone, by Application USD Million (2021-2026)
  • Table 368. Middle East Primidone, by Patient Type USD Million (2021-2026)
  • Table 369. Middle East Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 370. Middle East Primidone, by Dosage USD Million (2021-2026)
  • Table 371. Africa Primidone, by Application USD Million (2021-2026)
  • Table 372. Africa Primidone, by Patient Type USD Million (2021-2026)
  • Table 373. Africa Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 374. Africa Primidone, by Dosage USD Million (2021-2026)
  • Table 375. North America Primidone, by Country USD Million (2021-2026)
  • Table 376. North America Primidone, by Application USD Million (2021-2026)
  • Table 377. North America Primidone, by Patient Type USD Million (2021-2026)
  • Table 378. North America Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 379. North America Primidone, by Dosage USD Million (2021-2026)
  • Table 380. United States Primidone, by Application USD Million (2021-2026)
  • Table 381. United States Primidone, by Patient Type USD Million (2021-2026)
  • Table 382. United States Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 383. United States Primidone, by Dosage USD Million (2021-2026)
  • Table 384. Canada Primidone, by Application USD Million (2021-2026)
  • Table 385. Canada Primidone, by Patient Type USD Million (2021-2026)
  • Table 386. Canada Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 387. Canada Primidone, by Dosage USD Million (2021-2026)
  • Table 388. Mexico Primidone, by Application USD Million (2021-2026)
  • Table 389. Mexico Primidone, by Patient Type USD Million (2021-2026)
  • Table 390. Mexico Primidone, by Distribution Channel USD Million (2021-2026)
  • Table 391. Mexico Primidone, by Dosage USD Million (2021-2026)
  • Table 392. Primidone Sales: by Application(Tonne)
  • Table 393. Primidone Sales Epilepsy , by Region Tonne (2021-2026)
  • Table 394. Primidone Sales Essential Tremor , by Region Tonne (2021-2026)
  • Table 395. Primidone Sales Psychiatric Disorders , by Region Tonne (2021-2026)
  • Table 396. Primidone Sales: by Patient Type(Tonne)
  • Table 397. Primidone Sales Adult , by Region Tonne (2021-2026)
  • Table 398. Primidone Sales Pediatric , by Region Tonne (2021-2026)
  • Table 399. Primidone Sales: by Distribution Channel(Tonne)
  • Table 400. Primidone Sales Hospitals & Clinics , by Region Tonne (2021-2026)
  • Table 401. Primidone Sales Retail Pharmacies , by Region Tonne (2021-2026)
  • Table 402. Primidone Sales Online Pharmacies , by Region Tonne (2021-2026)
  • Table 403. Primidone Sales: by Dosage(Tonne)
  • Table 404. Primidone Sales 50mg , by Region Tonne (2021-2026)
  • Table 405. Primidone Sales 100mg , by Region Tonne (2021-2026)
  • Table 406. Primidone Sales 150mg , by Region Tonne (2021-2026)
  • Table 407. Primidone Sales 200mg , by Region Tonne (2021-2026)
  • Table 408. Primidone Sales 250mg , by Region Tonne (2021-2026)
  • Table 409. Primidone Sales Others , by Region Tonne (2021-2026)
  • Table 410. South America Primidone Sales, by Country Tonne (2021-2026)
  • Table 411. South America Primidone Sales, by Application Tonne (2021-2026)
  • Table 412. South America Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 413. South America Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 414. South America Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 415. Brazil Primidone Sales, by Application Tonne (2021-2026)
  • Table 416. Brazil Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 417. Brazil Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 418. Brazil Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 419. Argentina Primidone Sales, by Application Tonne (2021-2026)
  • Table 420. Argentina Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 421. Argentina Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 422. Argentina Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 423. Rest of South America Primidone Sales, by Application Tonne (2021-2026)
  • Table 424. Rest of South America Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 425. Rest of South America Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 426. Rest of South America Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 427. Asia Pacific Primidone Sales, by Country Tonne (2021-2026)
  • Table 428. Asia Pacific Primidone Sales, by Application Tonne (2021-2026)
  • Table 429. Asia Pacific Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 430. Asia Pacific Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 431. Asia Pacific Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 432. China Primidone Sales, by Application Tonne (2021-2026)
  • Table 433. China Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 434. China Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 435. China Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 436. Japan Primidone Sales, by Application Tonne (2021-2026)
  • Table 437. Japan Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 438. Japan Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 439. Japan Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 440. India Primidone Sales, by Application Tonne (2021-2026)
  • Table 441. India Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 442. India Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 443. India Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 444. South Korea Primidone Sales, by Application Tonne (2021-2026)
  • Table 445. South Korea Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 446. South Korea Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 447. South Korea Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 448. Taiwan Primidone Sales, by Application Tonne (2021-2026)
  • Table 449. Taiwan Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 450. Taiwan Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 451. Taiwan Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 452. Australia Primidone Sales, by Application Tonne (2021-2026)
  • Table 453. Australia Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 454. Australia Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 455. Australia Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 456. Rest of Asia-Pacific Primidone Sales, by Application Tonne (2021-2026)
  • Table 457. Rest of Asia-Pacific Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 458. Rest of Asia-Pacific Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 459. Rest of Asia-Pacific Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 460. Europe Primidone Sales, by Country Tonne (2021-2026)
  • Table 461. Europe Primidone Sales, by Application Tonne (2021-2026)
  • Table 462. Europe Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 463. Europe Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 464. Europe Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 465. Germany Primidone Sales, by Application Tonne (2021-2026)
  • Table 466. Germany Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 467. Germany Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 468. Germany Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 469. France Primidone Sales, by Application Tonne (2021-2026)
  • Table 470. France Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 471. France Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 472. France Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 473. Italy Primidone Sales, by Application Tonne (2021-2026)
  • Table 474. Italy Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 475. Italy Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 476. Italy Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 477. United Kingdom Primidone Sales, by Application Tonne (2021-2026)
  • Table 478. United Kingdom Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 479. United Kingdom Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 480. United Kingdom Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 481. Netherlands Primidone Sales, by Application Tonne (2021-2026)
  • Table 482. Netherlands Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 483. Netherlands Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 484. Netherlands Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 485. Rest of Europe Primidone Sales, by Application Tonne (2021-2026)
  • Table 486. Rest of Europe Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 487. Rest of Europe Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 488. Rest of Europe Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 489. MEA Primidone Sales, by Country Tonne (2021-2026)
  • Table 490. MEA Primidone Sales, by Application Tonne (2021-2026)
  • Table 491. MEA Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 492. MEA Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 493. MEA Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 494. Middle East Primidone Sales, by Application Tonne (2021-2026)
  • Table 495. Middle East Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 496. Middle East Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 497. Middle East Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 498. Africa Primidone Sales, by Application Tonne (2021-2026)
  • Table 499. Africa Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 500. Africa Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 501. Africa Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 502. North America Primidone Sales, by Country Tonne (2021-2026)
  • Table 503. North America Primidone Sales, by Application Tonne (2021-2026)
  • Table 504. North America Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 505. North America Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 506. North America Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 507. United States Primidone Sales, by Application Tonne (2021-2026)
  • Table 508. United States Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 509. United States Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 510. United States Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 511. Canada Primidone Sales, by Application Tonne (2021-2026)
  • Table 512. Canada Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 513. Canada Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 514. Canada Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 515. Mexico Primidone Sales, by Application Tonne (2021-2026)
  • Table 516. Mexico Primidone Sales, by Patient Type Tonne (2021-2026)
  • Table 517. Mexico Primidone Sales, by Distribution Channel Tonne (2021-2026)
  • Table 518. Mexico Primidone Sales, by Dosage Tonne (2021-2026)
  • Table 519. Research Programs/Design for This Report
  • Table 520. Key Data Information from Secondary Sources
  • Table 521. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Primidone: by Application USD Million (2015-2020)
  • Figure 5. Global Primidone: by Patient Type USD Million (2015-2020)
  • Figure 6. Global Primidone: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Primidone: by Dosage USD Million (2015-2020)
  • Figure 8. South America Primidone Share (%), by Country
  • Figure 9. Asia Pacific Primidone Share (%), by Country
  • Figure 10. Europe Primidone Share (%), by Country
  • Figure 11. MEA Primidone Share (%), by Country
  • Figure 12. North America Primidone Share (%), by Country
  • Figure 13. Global Primidone: by Application Tonne (2015-2020)
  • Figure 14. Global Primidone: by Patient Type Tonne (2015-2020)
  • Figure 15. Global Primidone: by Distribution Channel Tonne (2015-2020)
  • Figure 16. Global Primidone: by Dosage Tonne (2015-2020)
  • Figure 17. South America Primidone Share (%), by Country
  • Figure 18. Asia Pacific Primidone Share (%), by Country
  • Figure 19. Europe Primidone Share (%), by Country
  • Figure 20. MEA Primidone Share (%), by Country
  • Figure 21. North America Primidone Share (%), by Country
  • Figure 22. Global Primidone share by Players 2020 (%)
  • Figure 23. Global Primidone share by Players (Top 3) 2020(%)
  • Figure 24. Global Primidone share by Players (Top 5) 2020(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 27. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2020
  • Figure 28. Amneal Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 29. Amneal Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 30. Anda Repository Revenue, Net Income and Gross profit
  • Figure 31. Anda Repository Revenue: by Geography 2020
  • Figure 32. Lannett Co Inc (United States) Revenue, Net Income and Gross profit
  • Figure 33. Lannett Co Inc (United States) Revenue: by Geography 2020
  • Figure 34. Oxford Pharms (United States) Revenue, Net Income and Gross profit
  • Figure 35. Oxford Pharms (United States) Revenue: by Geography 2020
  • Figure 36. Hikma Pharmaceuticals PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. Hikma Pharmaceuticals PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 38. Watson Labs (United States) Revenue, Net Income and Gross profit
  • Figure 39. Watson Labs (United States) Revenue: by Geography 2020
  • Figure 40. Xcel Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 41. Xcel Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 42. Dr. Reddys Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 43. Dr. Reddys Laboratories (India) Revenue: by Geography 2020
  • Figure 44. Impax Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 45. Impax Laboratories (United States) Revenue: by Geography 2020
  • Figure 46. Global Primidone: by Application USD Million (2021-2026)
  • Figure 47. Global Primidone: by Patient Type USD Million (2021-2026)
  • Figure 48. Global Primidone: by Distribution Channel USD Million (2021-2026)
  • Figure 49. Global Primidone: by Dosage USD Million (2021-2026)
  • Figure 50. South America Primidone Share (%), by Country
  • Figure 51. Asia Pacific Primidone Share (%), by Country
  • Figure 52. Europe Primidone Share (%), by Country
  • Figure 53. MEA Primidone Share (%), by Country
  • Figure 54. North America Primidone Share (%), by Country
  • Figure 55. Global Primidone: by Application Tonne (2021-2026)
  • Figure 56. Global Primidone: by Patient Type Tonne (2021-2026)
  • Figure 57. Global Primidone: by Distribution Channel Tonne (2021-2026)
  • Figure 58. Global Primidone: by Dosage Tonne (2021-2026)
  • Figure 59. South America Primidone Share (%), by Country
  • Figure 60. Asia Pacific Primidone Share (%), by Country
  • Figure 61. Europe Primidone Share (%), by Country
  • Figure 62. MEA Primidone Share (%), by Country
  • Figure 63. North America Primidone Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bausch Health Companies Inc. (Canada)
  • Amneal Pharmaceuticals (United States)
  • Anda Repository
  • Lannett Co Inc (United States)
  • Oxford Pharms (United States)
  • Hikma Pharmaceuticals PLC (United Kingdom)
  • Watson Labs (United States)
  • Xcel Pharmaceuticals (United States)
  • Dr. Reddys Laboratories (India)
  • Impax Laboratories (United States)
Additional players considered in the study are as follows:
Mutual Pharmaceutical Co Inc (United States) , Vintage Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Feb 2021 249 Pages 50 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Primidone Market Quantitative research analysis
Global Primidone Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Primidone Market Report?

Have a Query? Click Here

Other Related Reports

Cytokine Release Syndrome Treatment Comprehensive Study by Type (Oral, Intravenously), Application (Hospitals, Homecare, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2028
$ 3500
Oral Hypoglycemic Drugs Comprehensive Study by Drugs (Generic, Branded), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Drug Class (Biguanides (Metformin), Sulfonyl...
$ 3750
Chronic Heart Failure (CHF) Drugs Comprehensive Study by Type (Anti-clotting (Aspirin), Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor), Anticoagulant Medicines (Warfarin), Blood Pres...
$ 3750
Propantheline Bromide Comprehensive Study by Application (Hyperhidrosis, Enuresis, Cramps or spasms of the stomach, Intestines or bladder), Drug type (Generic Drug, Patented Drug), Distribution Cha...
$ 3450
Lisinopril  Comprehensive Study by Patient Age (Paediatric (6 to 17 years), Adult (above 18 years)), Form (Solution, Tablet), Sales Channel (Online, Offline, Hospital Pharmacy, Retail Pharmacy), Dosa...
$ 3500
Dosulepin Comprehensive Study by Type (Tablets (75mg), Capsules (25mg)), Application (Depression Treatment, Anxiety Treatment, Others), Distribution Channel (Hospital, Drug Store, Online Store) Playe...
$ 3500